This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Fluorine-18-α-Methyltyrosine Positron Emission Tomography (18F-FMT PET) for Therapy Response in Lung Cancer

This study has been completed.
Information provided by:
Gunma University Identifier:
First received: January 20, 2009
Last updated: NA
Last verified: January 2009
History: No changes posted

L-[3-18F]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for positron emission tomography (PET). The investigators evaluated the value of 18F-FMT PET for the assessment of therapy response in patients with lung cancer as compared with that of 2-[18F]-fluoro-2-deoxy-D-glucose (18F-FDG) PET.

The patients with lung cancer underwent PET studies with 18F-FDG and 18F-FMT before and after radio-/chemotherapy. The investigators used the ratio of the SUVmax of the mediastinal (N2) lymph node to the SUVmax of the primary tumor (N/P ratio ). All patients were divided into two groups of N/P ratio<1 and N/P ratio≥1, and the survival time was estimated by Kaplan-Meier method.

Non-Small Cell Lung Cancer

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Fluorine-18-α-Methyltyrosine Positron Emission Tomography to Measure Therapy

Resource links provided by NLM:

Further study details as provided by Gunma University:

Therapy monitoring


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
This study was conducted at the Gunma University Hospital.

Inclusion Criteria:

  • primary lung cancer All patients received first-line chemotherapy

Exclusion Criteria:

  • Patients with diabetus mellitus
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00826033

Gunma University Graduate School of Medicine
Gunma, Japan, 371-8511
Sponsors and Collaborators
Gunma University
  More Information Identifier: NCT00826033     History of Changes
Other Study ID Numbers: Mol Imaing 1
Study First Received: January 20, 2009
Last Updated: January 20, 2009

Keywords provided by Gunma University:
Positron emission tomography
Lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Cariostatic Agents
Protective Agents
Physiological Effects of Drugs
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 19, 2017